Search Results

NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week.

Walden Biosciences, Inc. today announced that it has broadened its research collaboration with the University of Michigan at Ann Arbor (U-M).

Centene Corporation announced that its subsidiary, Meridian in Michigan, has been selected by the Michigan Department of Health and Human Services to continue to serve as a Medicaid health plan for the Comprehensive Health Care Program, which serves nearly 2 million Michiganders statewide.

NanoVibronix, Inc. today announced it has signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (“RCT”) study of UroShield.

Tryp Therapeutics Inc. is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of Michigan in a collaboration with Tryp Therapeutics.

Harvard Apparatus Regenerative Technology, Inc. announced that it officially activated the second site with University of Michigan for its clinical trial as to severe esophageal disease, being its first clinical trial in the United States.

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has executed an exclusive option agreement with the University of Michigan for the exclusive licensing of its innovative rectal expulsion device (RED).